Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL8415043 | 0.99 | EPHX2 (0.50) | EPHX2PARP1HTR2CHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL8703350 | 0.99 | EPHX2 (0.50) | EPHX2PARP1HTR2CHTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL9076651 | 0.97 | PARP1 (0.49) | EPHX2PARP1HTR2CHTR3EHTR3B | |
| Propionic Acid SCHEMBL9640910 | 0.91 | PARP1 (0.53) | EPHX2PARP1HTR2CHTR3EHTR3B | |
| SCHEMBL8917883 | 0.89 | EPHX2 (0.49) | EPHX2HTR2CHTR3EHTR3BHTR1A | |
| SCHEMBL10776859 | 0.87 | CYP1A2 (0.56) | PARP1 | |
| SCHEMBL8699158 | 0.85 | EPHX2 (0.51) | EPHX2HTR2CHTR3EHTR3BHTR1A | |
| SCHEMBL9640078 | 0.84 | PARP1 (0.47) | EPHX2PARP1HTR3EHTR3BHTR3A | |
| SCHEMBL9225056 | 0.84 | PARP1 (0.49) | PARP1 | |
| SCHEMBL9036740 | 0.83 | EPHX2 (0.55) | EPHX2HTR2CHTR3EHTR3BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0792153-B1 | COMPOSITIONS CONTAINING LAZAROIDS AND THEIR USE FOR PREVENTING ADHESIONS | UNIV SOUTHERN CALIFORNIA (US) | 2002-03-27 | — | — | EP | claimed |
| EP-0729948-B1 | The production of 3-alkylamino-2-piperazinylpyridines | UPJOHN CO (US) | 1999-09-01 | — | — | EP | claimed |
| EP-0690848-B1 | PIPERAZINYLPYRIDINYL WATER CLATHRATES | UPJOHN CO (US) | 1998-01-21 | — | — | EP | claimed |
| EP-0792153-A1 | COMPOSITIONS CONTAINING LAZAROIDS AND THEIR USE FOR PREVENTING ADHESIONS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1997-09-03 | — | — | EP | claimed |
| US-5614515-A | PREVENTING TISSUE ADHESION AFTER SURGERY | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1997-03-25 | — | — | US | claimed |
| WO-1996015795-A1 | COMPOSITIONS CONTAINING LAZAROIDS AND THEIR USE FOR PREVENTING ADHESIONS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1996-05-30 | — | — | WO | claimed |
| US-5322943-A | As substituents on steroids are useful as pharmaceutical agents for treating a number of conditions | THE UPJOHN COMPANY (US) | 1994-06-21 | — | — | US | claimed |
| WO-1991006542-A1 | PHARMACEUTICALLY ACTIVE AMINO-SUBSTITUTED HETEROARYL AMINES | THE UPJOHN COMPANY (US) | 1991-05-16 | — | — | WO | claimed |
| EP-0358676-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1990-03-21 | — | — | EP | claimed |
| EP-0293078-A1 | Pharmaceutically active amines | THE UPJOHN COMPANY (US) | 1988-11-30 | — | — | EP | claimed |
| WO-1988008424-A1 | PHARMACEUTICALLY ACTIVE AMINES | THE UPJOHN COMPANY (US) | 1988-11-03 | — | — | WO | claimed |
| EP-2078002-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| WO-1988007527-A1 | AMINO-9,10-SECOSTEROIDS | THE UPJOHN COMPANY (US) | 1988-10-06 | — | — | WO | disclosed |
| EP-0263213-A1 | C20 Through C26 amino steroids | THE UPJOHN COMPANY (US) | 1988-04-13 | — | — | EP | disclosed |
| EP-0238545-A1 | C 20? THROUGH C 26? AMINO STEROIDS. | UPJOHN CO (US) | 1987-09-30 | — | — | EP | disclosed |
| WO-1987001706-A2 | C20 THROUGH C26 AMINO STEROIDS | THE UPJOHN COMPANY (US) | 1987-03-26 | — | — | WO | disclosed |
| CN-86106226-A | 20-and 21-amino steroids | — | 1987-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | EPHX2 3023/4885PARP1 3624/4885HTR2C 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.